Compare EEX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | CSTL |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 806.3M |
| IPO Year | N/A | 2019 |
| Metric | EEX | CSTL |
|---|---|---|
| Price | $4.42 | $26.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.70 | ★ $47.17 |
| AVG Volume (30 Days) | 29.4K | ★ 422.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $16.88 | $2.10 |
| Revenue Next Year | $6.97 | $12.63 |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $3.22 | $14.59 |
| 52 Week High | $5.45 | $44.28 |
| Indicator | EEX | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 29.30 |
| Support Level | $3.42 | $21.77 |
| Resistance Level | $4.96 | $34.97 |
| Average True Range (ATR) | 0.23 | 1.68 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 50.00 | 13.48 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.